Choosing interventions to eliminate forest malaria: preliminary results of two operational research studies inside Cambodian forests.


Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
20 Jan 2021
Historique:
received: 19 10 2020
accepted: 24 12 2020
entrez: 21 1 2021
pubmed: 22 1 2021
medline: 7 8 2021
Statut: epublish

Résumé

Rapid elimination of Plasmodium falciparum malaria in Cambodia is a goal with both national and international significance. Transmission of malaria in Cambodia is limited to forest environments, and the main population at risk consists of forest-goers who rely on forest products for income or sustenance. The ideal interventions to eliminate malaria from this population are unknown. In two forested regions of Cambodia, forest-goers were trained to become forest malaria workers (FMWs). In one region, FMWs performed mass screening and treatment, focal screening and treatment, and passive case detection inside the forest. In the other region, FMWs played an observational role for the first year, to inform the choice of intervention for the second year. In both forests, FMWs collected blood samples and questionnaire data from all forest-goers they encountered. Mosquito collections were performed in each forest. Malaria prevalence by PCR was high in the forest, with 2.3-5.0% positive for P. falciparum and 14.6-25.0% positive for Plasmodium vivax among forest-goers in each study site. In vectors, malaria prevalence ranged from 2.1% to 9.6%, but no P. falciparum was observed. Results showed poor performance of mass screening and treatment, with sensitivity of rapid diagnostic tests equal to 9.1% (95% CI 1.1%, 29.2%) for P. falciparum and 4.4% (95% CI 1.6%, 9.2%) for P. vivax. Malaria infections were observed in all demographics and throughout the studied forests, with no clear risk factors emerging. Malaria prevalence remains high among Cambodian forest-goers, but performance of rapid diagnostic tests is poor. More adapted strategies to this population, such as intermittent preventive treatment of forest goers, should be considered.

Sections du résumé

BACKGROUND BACKGROUND
Rapid elimination of Plasmodium falciparum malaria in Cambodia is a goal with both national and international significance. Transmission of malaria in Cambodia is limited to forest environments, and the main population at risk consists of forest-goers who rely on forest products for income or sustenance. The ideal interventions to eliminate malaria from this population are unknown.
METHODS METHODS
In two forested regions of Cambodia, forest-goers were trained to become forest malaria workers (FMWs). In one region, FMWs performed mass screening and treatment, focal screening and treatment, and passive case detection inside the forest. In the other region, FMWs played an observational role for the first year, to inform the choice of intervention for the second year. In both forests, FMWs collected blood samples and questionnaire data from all forest-goers they encountered. Mosquito collections were performed in each forest.
RESULTS RESULTS
Malaria prevalence by PCR was high in the forest, with 2.3-5.0% positive for P. falciparum and 14.6-25.0% positive for Plasmodium vivax among forest-goers in each study site. In vectors, malaria prevalence ranged from 2.1% to 9.6%, but no P. falciparum was observed. Results showed poor performance of mass screening and treatment, with sensitivity of rapid diagnostic tests equal to 9.1% (95% CI 1.1%, 29.2%) for P. falciparum and 4.4% (95% CI 1.6%, 9.2%) for P. vivax. Malaria infections were observed in all demographics and throughout the studied forests, with no clear risk factors emerging.
CONCLUSIONS CONCLUSIONS
Malaria prevalence remains high among Cambodian forest-goers, but performance of rapid diagnostic tests is poor. More adapted strategies to this population, such as intermittent preventive treatment of forest goers, should be considered.

Identifiants

pubmed: 33472630
doi: 10.1186/s12936-020-03572-3
pii: 10.1186/s12936-020-03572-3
pmc: PMC7818569
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

51

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : French Initiative 5%
ID : 17SANIN205
Organisme : Regional Artemisinin-resistance Initiative
ID : QSE-M-UNOPS

Références

Lancet Infect Dis. 2018 May;18(5):565-572
pubmed: 29398388
Malar J. 2016 Mar 01;15:132
pubmed: 26931488
Stat Med. 2018 Mar 30;37(7):1191-1221
pubmed: 29226352
PLoS One. 2009 Oct 07;4(10):e7369
pubmed: 19809502
Clin Microbiol Rev. 2004 Jan;17(1):235-54
pubmed: 14726463
Malar J. 2019 Nov 27;18(1):379
pubmed: 31775755
PLoS One. 2012;7(1):e29991
pubmed: 22253852
Malar J. 2017 May 19;16(1):206
pubmed: 28526019
Southeast Asian J Trop Med Public Health. 2006;37 Suppl 2:1-128
pubmed: 17262930
Acta Trop. 2008 Jun;106(3):207-12
pubmed: 18471797
Am J Trop Med Hyg. 2015 Mar;92(3):573-7
pubmed: 25561570
Infect Dis Poverty. 2015 Dec 10;4:55
pubmed: 26654106
Trends Parasitol. 2019 Jun;35(6):388-398
pubmed: 31076353
Malar J. 2016 Mar 24;15:181
pubmed: 27013512
Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2 Suppl):12-7
pubmed: 11425173
PLoS One. 2015 Sep 09;10(9):e0124300
pubmed: 26352262
Am J Trop Med Hyg. 2020 Feb;102(2):307-309
pubmed: 31820711
Malar J. 2013 Nov 09;12:405
pubmed: 24206649
Trans R Soc Trop Med Hyg. 2018 Jun 1;112(6):264-271
pubmed: 29917147
Malar J. 2010 Feb 23;9:57
pubmed: 20175930
Malar J. 2019 Nov 27;18(1):376
pubmed: 31771587
J Infect Dis. 2018 Apr 23;217(10):1561-1568
pubmed: 29394367
Clin Infect Dis. 2018 Aug 31;67(6):817-826
pubmed: 29522113
Lancet Infect Dis. 2020 Dec;20(12):1470-1480
pubmed: 32679084
BMC Public Health. 2020 Apr 22;20(1):544
pubmed: 32321475
PLoS One. 2015 Sep 18;10(9):e0138735
pubmed: 26381896
Malar J. 2015 Jun 20;14:252
pubmed: 26088924
PLoS Med. 2019 Feb 15;16(2):e1002745
pubmed: 30768615
Heliyon. 2017 Nov 20;3(11):e00447
pubmed: 29202107
Malar J. 2017 Jan 31;16(1):56
pubmed: 28143518
Trends Parasitol. 2014 Apr;30(4):183-90
pubmed: 24642035
PLoS One. 2012;7(10):e45797
pubmed: 23049687
Philos Trans R Soc Lond B Biol Sci. 2015 Jun 5;370(1670):20140306
pubmed: 25918446
Am J Trop Med Hyg. 2019 May;100(5):1170-1178
pubmed: 30860021
Malar J. 2020 Apr 15;19(1):151
pubmed: 32293452

Auteurs

Amber Kunkel (A)

Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia. agkunkel@gmail.com.
Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France. agkunkel@gmail.com.

Chea Nguon (C)

National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia.

Sophea Iv (S)

Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Srean Chhim (S)

Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Dom Peov (D)

Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Phanith Kong (P)

Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Saorin Kim (S)

Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Sarun Im (S)

Partners for Development, Phnom Penh, Cambodia.

Mark Debackere (M)

Malaria Consortium, Phnom Penh, Cambodia.

Nimol Khim (N)

Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Jean Popovici (J)

Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Sreynet Srun (S)

Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Amélie Vantaux (A)

Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Jean-Olivier Guintran (JO)

World Health Organization, Cambodia Country Office, Phnom Penh, Cambodia.

Benoit Witkowski (B)

Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Patrice Piola (P)

Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH